0.0396SEK+5.88%Mkt Cap: 24.18M SEKP/E: —Last update: 2026-06-01
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiol…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap24.18M SEK
Enterprise Value15.24M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.65M SEK
Revenue/Share—
Last Price0.0396 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0010869552
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B18.70
EPS (TTM)-0.02
EPS (Forward)—
52W Range
0.023016% of range0.1300
52W High0.1300 SEK
52W Low0.0230 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-702.72%
ROA-86.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.22M SEK
CapEx (TTM)—
FCF Margin—
FCF Yield-16.36%
Net Debt-3.14M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.81
Quick Ratio0.77
Book Value/Sh0.0020 SEK
Cash/Share0.0060 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateMar 22, 2018
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.610.49M
Float491.63M
Insiders11.24%
Institutions4.49%
Technical
SMA 500.0412 (-3.8%)
SMA 2000.0356 (+11.1%)
Beta-0.71
S&P 52W Chg27.70%
Avg Vol (30d)3.61M
Avg Vol (10d)2.58M
Technical Indicators
RSI (14)44.7
MACD-0.0001
MACD Signal0.0001
MACD Hist.-0.0002
BB Upper0.0437 SEK
BB Middle0.0404 SEK
BB Lower0.0371 SEK
BB Width16.27%
ATR (14)0.0055 SEK
Vol Ratio (20d)0.62x